Member Info for howdlep

Great job by the IB team for recently bringing two sites up to speed on how to quantify pre- and post-surgical tumor volumes using proprietary Delta T1 maps. Critical info for neuro surgical teams & of prognostic importance!

https://twitter.com/IQAI_IB/status/1631648283989798913

is currently 3.6/3.67 for small. Let's see if we make a move higher today.

Trevor has always maintained and stated in regulated results, that he will continue to support the company by the issuing of CLN's. This is far better, pre profitability, than dilutive placings where broker clients sell short and flip for a quick return.
Also Trevor is restricted by a 'concert party' agreement with FAB, as result of family and friends being associated with FAB, so he is unable to buy shares on the open market without going over 30%. As a result he can only convert CLN's, providing the company with funds, while making a profit himself, dependent on the CLN conversion price. I am more than happy with this, particularly if shareholders are currently selling shares while expecting a placing to happen. If one doesn't happen, then they may be buying back their positions more expensively.
This is all very interesting.

As with any major shareholder of a listed company, Trevor is legally required to notify the market whenever his holding crosses a designated percentage threshold. This will be via a TR1.
If he sells shares but converts an equivelent number of shares via a CLN, no TR1 will be required. However, I would expect an RNS confirming its completion, as has been the case in the past.
Please note, grant availabilty will have increased as a result of the orphan drug status, which is excellent news.
The company is clearly in a far better position than it was when the share price was 22p. Now is the time for new and existing shareholders alike.

the breakout of sideways consolidation targeted 5.5p, which has been missed by 0.25p today. Above 5.5p targets 7.5p, which is the March resistance line projection. Bull argument remains while above July resistance at 4p.

https://tinyurl.com/n3dpvmnw

An excellent post Trek. People haven't understood the cost savings yet, but they will in time. The professional money hasn't even started to arrive yet.

is great news. Remember, the professional money hasn't begun to arrive yet because of the tiny market cap. However, today's FDA news is a huge de risk event for the company. We have suddendly become far more attractive to a predator.
Watch that volume tomorrow!

The FDA link is showing date designated as being the 27/2. Does anyone know what it was showing on the 26/2?

Designating an Orphan Product: Drugs and Biological Products

https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products

thanks for that link. I can reference now.

now 3.10 / 3.17 for small. Interest is building and MM's are bidding higher within the displayed spread. Something will give shortly.

Hi Tyke68,

Can you provide a link to the FDA website application, either here (if this bb allows the link) or over on advfn or twitter?

As for the benefits of orphan drug designation approval, this is from the latest RNS newsletter in January:-

Our sponsorship of the Phase I clinical trial of gallium maltolate (GaM) in the treatment of brain cancer remains a top priority. The screening and enrollment of subjects continue at an outstanding pace, and follow-up visits are increasing as more subjects remain on the study. In late 2022, an Orphan Drug Designation application for GaM was submitted to the US Food and Drug Administration (FDA). The FDA has 90 days to review the application. If granted, Orphan Drug Designation provides exclusive marketing and development rights, tax credits for clinical trial expenditures, and potential decreased wait-time for drug approval.

As per Kaneonaim, dated 20/2, the orphan drug designation application was submitted to the FDA on 12/12. So they have until 12/3 to approve or ask for further info. As the company have not advised re the latter, we now have less than 2 weeks to wait for a potential company transforming RNS. Now is the time to be accumulating imo.

https://twitter.com/howdlep/status/1627676991607406593

Congratulations on closing such an excellent acquisition. As a shareholder of Imaging Biometrics
@IQAI_IB, who are both a partner of @Blackford & have IB Clinic available on your Calantic platform, I am sure that #IQAI $IQAIF will benefit enormously from your combined expertise.

https://twitter.com/howdlep/status/1625404897079308288

Trek,
I agree entirely.
Phase 1 all about tolerance at 500mg, 1000mg and 1500mg and confirming phase 2 dosage levels.
As with all clinical trials, nothing is left to chance. Individuals and groups are fully assessed before progressing their treatment.
Regards
Philip

Zak notes the unfilled gap to the upside and the gap close buy signal at 3p and targets 5p-5.5p by the end of next month, this being the June projection line prediction.

https://tinyurl.com/3eurbrpe

Braveheart of course own 3.22% of Image Scan Holdings.
Unfortunately, BRH could not take a position in IQAI due to the 'concert party' rules. This would likely take Trevor over the 30% threshold.

A breakout of the pennant or flag consolidation on much higher volume is what is needed. Now if we were to get a nice supporting RNS, well the move could be a lot higher. Let's see if this continues into Monday. Certainly looking good at the moment.

as the market is bidding above the mid for 300k shares. Tickup coming.